Center-Authored Papers

Filters: Keyword is Androgen Antagonists  [Clear All Filters]
C
Cheng HH, Higano CS.  2014.  Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? Oncology (Williston Park, N.Y.). 28(8):700-1.
H
Harris WP, Mostaghel EA, Nelson PS, Montgomery B.  2009.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.. Nature clinical practice. Urology. 6(2):76-85. Abstract
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford DE, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al..  2013.  Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25. Abstract
M
Mendiratta P, Mostaghel EA, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.  2009.  Genomic strategy for targeting therapy in castration-resistant prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(12):2022-9. Abstract
Mostaghel EA, Montgomery B, Nelson PS.  2009.  Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.. Urologic oncology. 27(3):251-7. Abstract
S
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al..  2010.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.. The Journal of clinical investigation. 120(8):2715-30. Abstract
Y
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract